| 1 |
A Study to Evaluate Adverse Events and Change in Disease Activity in Participants Between 18 to 75 Years of Age Treated With Intravenous (IV) Infusion and Subcutaneous (SC) Injections of ABBV-154 for Moderately to Severely Active Crohn's Disease |
Crohn's Disease |
Drug: ABBV-154|Drug: Placebo |
AbbVie |
Phase 2 |
NCT05068284 |
2022-01-31 |
| 2 |
A Study of MK-1084 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With KRASG12C Mutant Advanced Solid Tumors (MK-1084-001) |
Advanced Solid Tumors |
Drug: MK-1084|Biological: Pembrolizumab |
Merck Sharp & Dohme LLC |
Phase 1 |
NCT05067283 |
2021-12-17 |
| 3 |
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65) |
Ovarian Cancer|Carcinoma, Ovarian Epithelial|Fallopian Tube Neoplasms |
Biological: Pembrolizumab|Drug: Paclitaxel|Drug: Bevacizumab|Other: Placebo for pembrolizumab|Drug: Docetaxel |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05116189 |
2021-12-13 |
| 4 |
NTLA-2002 in Adults With Hereditary Angioedema (HAE) |
Hereditary Angioedema |
Biological: Biological NTLA-2002|Other: Normal Saline IV Administration |
Intellia Therapeutics |
Phase 1|Phase 2 |
NCT05120830 |
2021-12-10 |
| 5 |
A Study of JNJ-73763989, JNJ-64300535, and Nucleos(t)Ide Analogs in Virologically Suppressed, Hepatitis B e Antigen (HBeAg)- Negative Participants With Chronic Hepatitis B Virus Infection |
Hepatitis B, Chronic |
Drug: JNJ-73763989|Biological: JNJ-64300535|Drug: ETV monohydrate|Drug: Tenofovir disoproxil|Drug: TAF |
Janssen Research & Development, LLC |
Phase 1 |
NCT05123599 |
2021-12-06 |
| 6 |
A Study to Evaluate HB0034 in Healthy Adult Participants |
Healthy |
Drug: HB0034|Drug: Placebo |
Shanghai Huaota Biopharmaceutical Co., Ltd. |
Phase 1 |
NCT05064345 |
2021-12-03 |
| 7 |
MK-1654 in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007) |
RSV Infection |
Biological: MK-1654|Biological: Palivizumab|Biological: Placebo |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT04938830 |
2021-11-30 |
| 8 |
Immunogenicity and Safety Study of SK SARS-CoV-2 Recombinant Nanoparticle Vaccine (GBP510) Adjuvanted With AS03 (COVID-19) |
Covid19 |
Biological: GBP510 adjuvanted with AS03 (Receptor-Binding Domain(RBD) 25ug/dose)|Biological: ChAdOx1-S not less than 2.5 횞 10^8 infectious units |
SK Bioscience Co., Ltd.|International Vaccine Institute|GlaxoSmithKline|Coalition for Epidemic Preparedness Innovations |
Phase 3 |
NCT05007951 |
2021-08-30 |
| 9 |
Safety and Immunogenicity of VLA2001 Adults Aged ??6 Years |
SARS-CoV-2 Virus Infection |
Biological: VLA2001 |
Valneva Austria GmbH |
Phase 3 |
NCT04956224 |
2021-08-09 |
| 10 |
A Study of an Adenovirus Serotype 26 Pre-fusion Conformation-stabilized F Protein (Ad26. RSV. preF) Based Respiratory Syncytial Virus (RSV) Vaccine in the Prevention of Lower Respiratory Tract Disease in Adults Aged 60 Years and Older |
Respiratory Syncytial Viruses|Lower Respiratory Tract Disease |
Biological: Adenovirus serotype 26 (Ad26)-based respiratory syncytial virus (RSV). preF|Biological: Placebo |
Janssen Vaccines & Prevention B.V. |
Phase 3 |
NCT04908683 |
2021-07-21 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.